Laxmi Dental Ltd Q2 FY26 – The Tooth Fairy Turns Profitable: ₹72.3 Cr Revenue (+26.5% YoY), ₹8.53 Cr PAT (+44.8%), and Still No Dividend in Sight!
1. At a Glance
Laxmi Dental Ltd has once again shown that smiles sell — especially when they’re digitally designed, 3D-printed, and priced at a P/E of 66.4. The company clocked ₹72.27 crore in Q2 FY26 revenue (+26.5% YoY) and ₹8.53 crore PAT (+44.8% YoY), continuing its run as India’s only fully integrated dental products manufacturer. The market rewarded this with a ₹1,710 crore market cap — not bad for a business that started out fixing teeth and now fixes balance sheets.
At ₹311 per share, the stock trades at 7.46x book value, a valuation that could make even orthodontists squint. Debt is barely noticeable at ₹8.9 crore, giving it a breezy Debt/Equity of just 0.04. ROE stands tall at 21.9%, ROCE at 19.2%, and the company is sitting on a fat current ratio of 4.42 — meaning it’s got enough liquidity to buy all the floss in India and still have spare cash.
As the Bible says, “A cheerful heart is good medicine.” (Proverbs 17:22) — and clearly, Laxmi Dental’s profits have found a way to keep shareholders’ hearts, if not their wallets, happy.
Still, there’s a cavity: despite consistent profits and IPO cash, no dividends yet. Investors are left waiting like dental patients post-anesthesia — hopeful, slightly numb, and staring at the clock.
2. Introduction
Once upon a time, dental care meant a dentist, a drill, and a prayer. But then came Laxmi Dental, India’s very own tooth-tech marvel. Incorporated in 2004 and listed in January 2025, the company has quietly built a ₹1,700 crore empire of smiles — powered by zirconia crowns, clear aligners, and a global network of 20,000+ dentists.
The Q2 FY26 numbers prove that even in healthcare, aesthetics pay. The company’s aligner business (28% of FY24 revenue) is now biting into serious market share, while its legacy laboratory business still holds the crown (pun intended) with ~65% contribution. Add to that a growing export footprint in 95 countries, including the U.S. and U.K., and Laxmi Dental’s reach is now wider than your dentist’s mouth mirror.
But here’s the twist — this isn’t just a manufacturing story. It’s a B2B2C business model masterclass, where dentists become influencers. Instead of expensive ad campaigns, Laxmi relies on 20,000 clinics to recommend its aligners and products. Why spend on marketing when your customers do it for you?
If there were a Shark Tank episode on “how to scale smiles,” Laxmi Dental would probably walk away with all the funding — and offer veneers to the sharks as part of the deal.
3. Business Model – WTF Do They Even Do?
Let’s decode the magic behind those pearly profits.
Laxmi Dental operates across three core business segments — all shiny and surprisingly profitable:
a) Laboratory Business (64.75% of FY24 revenue): The company manufactures custom-made crowns, bridges, and dentures under the “Illusion Zirconia” brand. Essentially, it’s the tech-savvy cousin of your local dental lab — just with robots, scanners, and FDA registrations.
b) Aligner Solutions (28.12%): The company’s “Illusion Aligners” and “Taglus” brands cater to orthodontic treatment without metal braces. Think of it as the Invisalign of India — except locally made and exported to the U.S.
c) Pediatric Dental Products: Sold under the “Kids-E-Dental” brand, this segment makes pre-formed crowns and accessories for children, because even milk teeth deserve swag.
The company runs six manufacturing units — three in Mira Road (Mumbai region), two in Boisar, and one in Kochi — covering 147,000 sq. ft. Add five support facilities in Delhi, Bengaluru, Ahmedabad, and Mumbai, and you’ve got a dental network more widespread than Swiggy’s delivery map.
In FY24, branded products contributed 38.28% of revenue, proving that even dentists can build brand equity — not just root canals.
And geographically? 67% of revenue comes from India, 19% from the U.S., 7% from the U.K., and the rest from others. Basically, your molar restoration could be Made in Mira Road, sold in Manchester, and marketed on Instagram by a Mumbai dentist.
4. Financials Overview
Source table
Metric (₹ Cr)
Q2 FY26 (Sep 2025)
Q2 FY25 (Sep 2024)
Q1 FY26 (Jun 2025)
YoY %
QoQ %
Revenue
72.3
57.1
65.6
+26.5%
+10.2%
EBITDA
11.0
8.7
11.9
+26.4%
-7.4%
PAT
8.53
5.9
8.33
+44.8%
+2.4%
EPS (₹)
1.55
1.12
1.53
+38.4%
+1.3%
YoY growth is glowing like a whitening ad, while QoQ shows steady molar movement. The 26% topline growth reflects healthy expansion in both domestic and export orders. EBITDA margins held steady around 15–18%, a sign that pricing power isn’t being drilled away.
The only painful figure? A P/E of 66.4 — because apparently, even valuations are getting cosmetic treatments now.
5. Valuation Discussion – Fair Value Range (Educational)
Let’s floss through the numbers.
a) P/E Method: FY25 EPS = ₹4.78 Industry P/E = 44 → Fair Range = ₹4.78 × (45–55) = ₹215–₹262
b) EV/EBITDA Method: EV = ₹1,694 crore FY25 EBITDA = ₹43 crore → EV/EBITDA = 39.4× Peers trade near 25–30× → → Fair Value Range = ₹1,100–₹1,300 crore EV ≈ ₹210–₹250 per share
c) Simplified DCF (Growth 15%, WACC 11%) → ₹220–₹260 per share
🎯 Educational Fair Value Range: ₹215 – ₹260 per share This range is for educational purposes only, not investment advice.
6. What’s Cooking – News, Triggers, Drama
It’s been a headline-heavy 2025 for Laxmi Dental — almost like a soap opera in scrubs.
Nov 2025: Q2 results declared – revenue ₹72.27 crore, PAT ₹8.53 crore, +26.5%
